Will New Injectables Sell In An Oral, Mainly Generic Cholesterol World?

PCSK9 inhibitors have come into vogue based on potent LDL-lowering in early studies. But the up-and-coming biologics still face questions about how they will fit in a market dominated largely by proven, oral generics.